Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YWHAZ | P63104 | 3/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8582014 | 1.00 | YWHAZ (0.32) | YWHAZCA1CA2CA9 | |
| SCHEMBL4205268 | 0.89 | YWHAZ (0.36) | YWHAZCA1CA2CA9 | |
| SCHEMBL13909435 | 0.89 | YWHAZ (0.36) | YWHAZCA1CA2CA9 | |
| SCHEMBL7886992 | 0.81 | ALDH1A1 (0.36) | CA1CA2 | |
| SCHEMBL7567193 | 0.81 | ALDH1A1 (0.36) | CA1CA2 | |
| SCHEMBL7889397 | 0.81 | ALDH1A1 (0.36) | CA1CA2 | |
| SCHEMBL3933081 | 0.81 | YWHAZ (0.32) | YWHAZCA1CA2CA9 | |
| SCHEMBL16135486 | 0.80 | CA2 (0.36) | YWHAZCA1CA2CA9 | |
| SCHEMBL8435871 | 0.80 | CA2 (0.36) | YWHAZCA1CA2CA9 | |
| SCHEMBL15279231 | 0.80 | L3MBTL1 (0.37) | YWHAZCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6511965-B2 | For therapy and prophylaxis of inflammatory disorders, autoimmune diseases or septicemia | SANKYO COMPANY, LIMITED (JP) | 2003-01-28 | — | — | US | disclosed |
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | SANKYO COMPANY, LIMITED (JP) | 2002-10-31 | — | — | US | disclosed |
| EP-1152007-A1 | ETHER TYPE LIPID A1-CARBOXYLIC ACID ANALOGUES | Sankyo Company, Limited (JP) | 2001-11-07 | — | — | EP | disclosed |
| US-5792840-A | SUBSTITUTED GLUCOPYRANOSYL PHOSPHATES | SANKYO COMPANY, LIMITED (JP) | 1998-08-11 | — | — | US | disclosed |
| EP-0437016-B1 | Lipid A analogues having immunoactivating and anti-tumour activity | SANKYO CO (JP) | 1996-05-01 | — | — | EP | disclosed |
| EP-0437016-A2 | Lipid A analogues having immunoactivating and anti-tumour activity | Sankyo Company Limited (JP) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161221-A1 | Ether type lipid a 1-carboxylic acid analogs | MSR1, ELOVL1, FFAR1 | YWHAZ 2584/4885CA1 1334/4885CA2 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.